Navigation Links
Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age

New Study Results Show Antibodies Against Cancer-Causing Virus Types 16 & 18 That Are At Least Ten Times Greater Than Natural Infection Levels

CHICAGO, June 05, 2007 /PRNewswire/ -- New Phase III data show that at 18 months after the first of a three-dose regimen, 100 percent of women up to age 55 vaccinated with the GlaxoSmithKline (GSK) cervical cancer candidate vaccine had antibodies present against the two most common cancer-causing human papillomavirus types, 16 and 18. These data indicate that the vaccine, formulated with a proprietary adjuvant system called AS04, is highly immunogenic and generally well-tolerated, with antibody levels at least ten times greater than those produced by natural infection. These new extended follow-up data were presented today at the American Society of Clinical Oncology (ASCO) annual meeting (abstract #3007).

"Previous natural infection with these cancer-causing human papillomavirus types may not confer lifelong protection. Thus, women of all ages may be at risk for future infection," said Prof. Tino F. Schwarz, Stiftung Juliusspital, Wuerzburg, Germany, the lead study investigator. "In fact, the older a woman is when infected, the more likely that the infection will become persistent, which may lead to the development of precancerous lesions. These GSK cervical cancer vaccine study results suggest that many women could potentially benefit from vaccination against cervical cancer."

Furthermore, the study shows that antibody levels in women ages 26 to 55 against cancer-causing virus types 16 and 18 were in the same range as observed in a separate study. That study demonstrated that the GSK cervical cancer vaccine provided 100 percent sustained protection against precancerous lesions caused by these virus types for up to 5.5 years in women ages 15 to 25.

"The results of this study are very promising, as we observed that 100 percent of women in all age groups showed a persistent antibody response to our vaccine," said Barbara Howe, MD, Vice President and Director, North American Vaccine Development Organization, GlaxoSmithKline. "As women age, their immune responses typically decline. We designed our cervical cancer vaccine with an adjuvant system called AS04 which is specifically intended to enhance immune response and increase duration of protection."

Notes to editors:

About the study

Healthy women from Germany and Poland ages 15 to 55 who received three doses of the GSK cervical cancer candidate vaccine at 0, 1 and 6 months in this Phase III clinical study were invited to participate in an extension to the initial study, previously evaluated at 12 months. The 517 women who participated in this follow-up study were age-stratified: 15-25 [n=169], 26-35 [n=83], 36-45 [n=89] and 46-55 [n=176] years old. Immunogenicity and safety were assessed at 18 months after the first dose of a three-dose vaccination regimen.

About the GSK cervical cancer candidate vaccine

GSK submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for CERVARIX(R) in March 2007, for the prevention of cervical cancer and precancerous lesions associated with the most common cancer-causing human papillomavirus types. The BLA includes data from clinical trials in almost 30,000 females ages 10-55 and reflects an ethnically diverse population. The submission also contains data from the largest Phase III cervical cancer vaccine efficacy trial to date, which was conducted around the world in more than 18,000 women ages 15-25. In May, CERVARIX(R) was granted a license by the Therapeutic Goods Administration (TGA) of Australia for the prevention of cervical cancer and precancerous lesions caused by human papillomavirus types 16 and 18 for use in females ages 10-45 years. GSK has also submitted marketing authorization applications to the European Medicines Agency, Canada and numerou s countries in Asia and Latin America.

About cervical cancer

Worldwide, more than 500,000 women are diagnosed with cervical cancer and over 280,000 women die from it each year. In the United States, after breast cancer, cervical cancer is the leading cause of cancer death in women ages 20- 39. Furthermore, approximately two million precancerous lesions are diagnosed each year in the U.S. Cervical cancer and precancerous lesions are a major health, psychological and social burden on women everywhere.

At any given time, only 2.3 percent of women ages 14-59 are currently infected with cancer-causing human papillomavirus types 16 or 18. Only 0.1 percent is currently infected with both types. Therefore, the vast majority of these women (up to 99.9 percent) may benefit from vaccination as they are potentially at risk for developing an infection in the future with these types. Naturally occurring infections with cancer-causing virus types may resolve on their own, but this previous exposure may not protect against future infections with the same virus types. Some infections persist and develop into precancerous lesions, which can advance into cancer. Progression from infection to cervical cancer may take as little as two years.

About GlaxoSmithKline

GlaxoSmithKline-one of the world's leading research-based pharmaceutical and healthcare companies-is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, please visit

GSK Biologicals (GSK Bio), one of the world's leading vaccine manufacturers, is headquartered in Rixensart, Belgium, where the majority of GlaxoSmithKline's activities in the field of vaccine research, development and production are conducted. GSK Bio employs more than 1,500 scientists, who are devoted to discovering new vaccines and developing more cost-effective and c onvenient combination products to prevent infections that cause serious medical problems worldwide. In 2006, GSK Bio distributed more than 1.1 billion doses of vaccines to 169 countries in both the developed and the developing world - an average of 3 million doses a day. Of those vaccine doses, approximately 136 million were doses of combination pediatric vaccines which protect the world's children from up to six diseases in one vaccine.

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company, including those made in this Announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group's operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2006.


     U.S. Media inquiries:                  Liad Diamond    +1 919 483 2839

                                            Nancy Pekarek   +1 919 483 2839

                                            Alice Hunt      +1 919 483 2839

     UK Media inquiries:                    Philip Thomson  +44 20 8047 5502

                                            Gwenan White    +44 20 8047 5502

                                            Joss Mathieson  +44 20 8047 5502

     US Analyst/Investor inquiries:         Frank Murdolo   +1 215 751 7002

                                            Tom Curry       +1 215 751 5419,

     European Analyst/Investor inquiries:   Anita Kidgell   +44 20 8047 5542

                                            Sally Ferguson  +44 20 8047 5543

                                            David Mawdsley  +44 20 8047 5564

CONTACT: U.S. Media inquiries: Liad Diamond, +1 919 483 2839, NancyPekarek, +1 919 483 2839, Alice Hunt, +1 919 483 2839, UK Media inquiries:Philip Thomson, +44 20 8047 5502, Gwenan White, +44 20 8047 5502, JossMathieson, +44 20 8047 5502, US Analyst - Investor inquiries: FrankMurdolo, +1 215 751 7002, Tom Curry, +1 215 751 5419, European Analyst -Investor inquiries: Anita Kidgell, +44 20 8047 5542, Sally Ferguson, +44 208047 5543, David Mawdsley, +44 20 8047 5564

Web site:

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100 Percent Protection Against Precancerous Lesions Caused By Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than Five Years
2. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
3. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
4. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
5. Nventa Announces Presentation of Positive HspE7 Data from NCI-Sponsored Clinical Trial in Cervical Dysplasia
6. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
Post Your Comments:
(Date:10/8/2015)... 8, 2015  Ardelyx, Inc. (NASDAQ: ARDX ... and cardio-renal diseases, today announced that clinical data ... be presented at the 2015 American College of ... measures of sustained response in IBS-C patients enrolled ... Phase 2 trial. The meeting will be held ...
(Date:10/8/2015)... 2015  Allergan plc (NYSE: AGN ), a ... hold its R&D Day on November 4, from 11:00 ... 1:00 p.m. PT). The company will also host its ... a.m. ET (6:00 a.m. PT). ... --> Logo - ...
(Date:10/8/2015)... , Oct. 8, 2015  The National ... approximately $40 million to the Broad Institute of ... sequencing of 20,000 individuals, as well as data ... metabolite profiling. Trans-Omics for Precision Medicine ... step toward a larger initiative, which will use ...
Breaking Medicine Technology:
... MELVILLE, N.Y., April 23, 2012  Henry Schein, ... provider of health care products and services to dental, ... with the launch of its 2012 Global Reflections program ... "Henry Schein firmly believes that protecting ...
... Systems, Inc. (NASDAQ: DCTH ) today announced it ... revolver with Silicon Valley Bank ("SVB"), a leading provider of ... available for general corporate purposes supporting the overall growth and ... transaction, Eamonn P. Hobbs, President & CEO of Delcath Systems, ...
Cached Medicine Technology:
(Date:10/9/2015)... ... ... A new health tool that helps identify if a sore throat is serious, ... just in time for the cold and flu season, which the Center for Disease ... U.S., the real start of cold/flu season is the start of the school year, ...
(Date:10/9/2015)... ... October 09, 2015 , ... Smoke alarms can save lives. In fact, ... risk of dying in reported home fires in half. As part of Fire Prevention ... are property installed and maintained. , Half of home fire deaths result from fires ...
(Date:10/9/2015)... Huntington Beach, CA (PRWEB) , ... October 09, ... ... Rassouli, is now offering a special promotion on Invisalign, the orthodontic system that ... many reasons. The aligners are almost invisible against the teeth, which allow patients ...
(Date:10/9/2015)... ... October 09, 2015 , ... Matrix IT ... product specifications for TRACTUS, the world’s first sterile field scanner. , ... response to the FDA’s recent Unique Device Identifier (UDI) Final Rule, which will ...
(Date:10/9/2015)... Washington, DC (PRWEB) , ... October 09, 2015 , ... ... agreement from the US Centers for Disease Control and Prevention (CDC) to improve the ... 14 years that AAFA has been awarded a project by the CDC and allows ...
Breaking Medicine News(10 mins):
... Network of America, LLC (DNoA) announced today the completion ... Blue Cross Blue Shield of Michigan (BCBSM), a nonprofit ... in Michigan, in addition to members of Michigan-headquartered groups ... , The acquisition brings two strategically focused companies -- ...
... BCBSM Customers Expanded National Dental Network; Solidify BCBSM Position as ... July 1 Blue Cross Blue Shield of Michigan announced ... acquired by Dental Network of America, LLC (DNoA), a strategic ... and DNoA -- will provide BCBSM with a more competitive ...
... , WASHINGTON, July 1 Today,s 65 year old Medicare ... or ,donut hole, is eliminated, says a new analysis of ... Avalere Health. The firm also concludes that although fewer ... by 2020 some of the sickest Medicare beneficiaries will spend ...
... 1 At a bargaining session yesterday with SEIU ... at Kaiser Permanente facilities in California and the rest ... ended when the contractor refused to restore the affordable ... the year. Bargaining broke down Tuesday evening as ...
... the 2009 pistachio harvest little more than two months away, ... with production expected to exceed 2008 levels. Growing conditions have ... of nutrient-rich pistachios to meet increasing demand. , ... September and is estimated at more than 425 million pounds ...
... , WESTCHESTER, Ill., July 1 The Pediatric Brain Tumor ... Fund) and BrainLAB teamed up again this year for the ... in New York City. The June 6 event raised funds ... childhood brain tumors. , , (Photo: ...
Cached Medicine News:
... Tri-Flo® suction catheter design was created ... patients while still providing high suctioning ... (5/6, 8 or 10 Fr) feature ... catheter placement. Our complete catheter line ...
Tracheal Suction Latex Rubber Catheters - Funnel End...
Rubber bronchial coude catheter, X-ray opaque, one eye, whistle tip....
KCIs KinAir IV combines Advanced Pressure Relief Therapy with a manual wound care turn to provide optimum skin care and patient,positioning....
Medicine Products: